APO Research
Talk to an analyst

APO RESEARCH · REPORT

Medulloblastoma Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Medulloblastoma Drug Industry Growth and Trends Forecast to 2032

22 December 2025100 pages

Choose your research edition.

Industry ResearchMedulloblastoma Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Medulloblastoma Drug Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Medulloblastoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medulloblastoma Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Medulloblastoma Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Medulloblastoma Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Medulloblastoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Medulloblastoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Medulloblastoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Medulloblastoma Drug include DelMar Pharmaceuticals Inc, Ignyta Inc, IMPACT Therapeutics Inc, Lipocure Ltd, MacroGenics Inc, NewLink Genetics Corp, Novogen Ltd, Ono Pharmaceutical Co Ltd and Progenics Pharmaceuticals Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Medulloblastoma Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Medulloblastoma Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Medulloblastoma Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Medulloblastoma Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Medulloblastoma Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Medulloblastoma Drug Market by Company

DelMar Pharmaceuticals Inc

Ignyta Inc

IMPACT Therapeutics Inc

Lipocure Ltd

MacroGenics Inc

NewLink Genetics Corp

Novogen Ltd

Ono Pharmaceutical Co Ltd

Progenics Pharmaceuticals Inc

Stemline Therapeutics Inc

ThromboGenics NV

VBI Vaccines Inc

Bristol-Myers Squibb Company

Bayer AG

Medulloblastoma Drug Segment by Type

Ipilimumab

Dianhydrogalactitol

Indoximod

IMP-5471

Others

Medulloblastoma Drug Segment by Application

Hospital

Clinic

Others

Medulloblastoma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medulloblastoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medulloblastoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medulloblastoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Medulloblastoma Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Medulloblastoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Ipilimumab Table 2. Major Company of Dianhydrogalactitol Table 3. Major Company of Indoximod Table 4. Major Company of IMP-5471 Table 5. Major Company of Others Table 6. Global Medulloblastoma Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Medulloblastoma Drug Sales by Type (2021-2026) & (k units) Table 8. Global Medulloblastoma Drug Sales Market Share in Volume by Type (2021-2026) Table 9. Global Medulloblastoma Drug Sales by Type (2021-2026) & (US$ Million) Table 10. Global Medulloblastoma Drug Sales Market Share in Value by Type (2021-2026) Table 11. Global Medulloblastoma Drug Price by Type (2021-2026) & (US$/unit) Table 12. Global Medulloblastoma Drug Sales by Type (2027-2032) & (k units) Table 13. Global Medulloblastoma Drug Sales Market Share in Volume by Type (2027-2032) Table 14. Global Medulloblastoma Drug Sales by Type (2027-2032) & (US$ Million) Table 15. Global Medulloblastoma Drug Sales Market Share in Value by Type (2027-2032) Table 16. Global Medulloblastoma Drug Price by Type (2027-2032) & (US$/unit) Table 17. North America Medulloblastoma Drug Sales by Type (2021-2026) & (k units) Table 18. North America Medulloblastoma Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Medulloblastoma Drug Sales by Type (2021-2026) & (k units) Table 20. Europe Medulloblastoma Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Medulloblastoma Drug Sales by Type (2021-2026) & (k units) Table 22. Asia-Pacific Medulloblastoma Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Medulloblastoma Drug Sales by Type (2021-2026) & (k units) Table 24. Latin America Medulloblastoma Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Medulloblastoma Drug Sales by Type (2021-2026) & (k units) Table 26. Middle East and Africa Medulloblastoma Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Medulloblastoma Drug Industry Trends Table 28. Medulloblastoma Drug Industry Drivers Table 29. Medulloblastoma Drug Industry Opportunities and Challenges Table 30. Medulloblastoma Drug Industry Restraints Table 31. Global Medulloblastoma Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Medulloblastoma Drug Revenue Market Share by Company (2021-2026) Table 33. Global Medulloblastoma Drug Sales by Company (2021-2026) & (k units) Table 34. Global Medulloblastoma Drug Sales Share by Company (2021-2026) Table 35. Global Medulloblastoma Drug Market Price by Company (2021-2026) & (US$/unit) Table 36. Global Medulloblastoma Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Medulloblastoma Drug Major Company Production Sites and Headquarters Table 38. Global Medulloblastoma Drug Company, Product Type & Application Table 39. Global Medulloblastoma Drug Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Medulloblastoma Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Medulloblastoma Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Medulloblastoma Drug Sales by Region (2021-2026) & (k units) Table 44. Global Medulloblastoma Drug Sales Market Share in Volume by Region (2021-2026) Table 45. Global Medulloblastoma Drug Sales by Region (2021-2026) & (US$ Million) Table 46. Global Medulloblastoma Drug Sales Market Share in Value by Region (2021-2026) Table 47. Global Medulloblastoma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 48. Global Medulloblastoma Drug Sales by Region (2027-2032) & (k units) Table 49. Global Medulloblastoma Drug Sales Market Share in Volume by Region (2027-2032) Table 50. Global Medulloblastoma Drug Sales by Region (2027-2032) & (US$ Million) Table 51. Global Medulloblastoma Drug Sales Market Share in Value by Region (2027-2032) Table 52. Global Medulloblastoma Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 53. Global Medulloblastoma Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Medulloblastoma Drug Sales by Application (2021-2026) & (k units) Table 55. Global Medulloblastoma Drug Sales Market Share in Volume by Application (2021-2026) Table 56. Global Medulloblastoma Drug Sales by Application (2021-2026) & (US$ Million) Table 57. Global Medulloblastoma Drug Sales Market Share in Value by Application (2021-2026) Table 58. Global Medulloblastoma Drug Price by Application (2021-2026) & (US$/unit) Table 59. Global Medulloblastoma Drug Sales by Application (2027-2032) & (k units) Table 60. Global Medulloblastoma Drug Sales Market Share in Volume by Application (2027-2032) Table 61. Global Medulloblastoma Drug Sales by Application (2027-2032) & (US$ Million) Table 62. Global Medulloblastoma Drug Sales Market Share in Value by Application (2027-2032) Table 63. Global Medulloblastoma Drug Price by Application (2027-2032) & (US$/unit) Table 64. North America Medulloblastoma Drug Sales by Application (2021-2026) & (k units) Table 65. North America Medulloblastoma Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Medulloblastoma Drug Sales by Application (2021-2026) & (k units) Table 67. Europe Medulloblastoma Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Medulloblastoma Drug Sales by Application (2021-2026) & (k units) Table 69. Asia-Pacific Medulloblastoma Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Medulloblastoma Drug Sales by Application (2021-2026) & (k units) Table 71. Latin America Medulloblastoma Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Medulloblastoma Drug Sales by Application (2021-2026) & (k units) Table 73. Middle East and Africa Medulloblastoma Drug Sales by Application (2021-2026) & (US$ Million) Table 74. DelMar Pharmaceuticals Inc Company Information Table 75. DelMar Pharmaceuticals Inc Business Overview Table 76. DelMar Pharmaceuticals Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. DelMar Pharmaceuticals Inc Medulloblastoma Drug Product Portfolio Table 78. DelMar Pharmaceuticals Inc Recent Development Table 79. Ignyta Inc Company Information Table 80. Ignyta Inc Business Overview Table 81. Ignyta Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Ignyta Inc Medulloblastoma Drug Product Portfolio Table 83. Ignyta Inc Recent Development Table 84. IMPACT Therapeutics Inc Company Information Table 85. IMPACT Therapeutics Inc Business Overview Table 86. IMPACT Therapeutics Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. IMPACT Therapeutics Inc Medulloblastoma Drug Product Portfolio Table 88. IMPACT Therapeutics Inc Recent Development Table 89. Lipocure Ltd Company Information Table 90. Lipocure Ltd Business Overview Table 91. Lipocure Ltd Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Lipocure Ltd Medulloblastoma Drug Product Portfolio Table 93. Lipocure Ltd Recent Development Table 94. MacroGenics Inc Company Information Table 95. MacroGenics Inc Business Overview Table 96. MacroGenics Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. MacroGenics Inc Medulloblastoma Drug Product Portfolio Table 98. MacroGenics Inc Recent Development Table 99. NewLink Genetics Corp Company Information Table 100. NewLink Genetics Corp Business Overview Table 101. NewLink Genetics Corp Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. NewLink Genetics Corp Medulloblastoma Drug Product Portfolio Table 103. NewLink Genetics Corp Recent Development Table 104. Novogen Ltd Company Information Table 105. Novogen Ltd Business Overview Table 106. Novogen Ltd Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Novogen Ltd Medulloblastoma Drug Product Portfolio Table 108. Novogen Ltd Recent Development Table 109. Ono Pharmaceutical Co Ltd Company Information Table 110. Ono Pharmaceutical Co Ltd Business Overview Table 111. Ono Pharmaceutical Co Ltd Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Ono Pharmaceutical Co Ltd Medulloblastoma Drug Product Portfolio Table 113. Ono Pharmaceutical Co Ltd Recent Development Table 114. Progenics Pharmaceuticals Inc Company Information Table 115. Progenics Pharmaceuticals Inc Business Overview Table 116. Progenics Pharmaceuticals Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Progenics Pharmaceuticals Inc Medulloblastoma Drug Product Portfolio Table 118. Progenics Pharmaceuticals Inc Recent Development Table 119. Stemline Therapeutics Inc Company Information Table 120. Stemline Therapeutics Inc Business Overview Table 121. Stemline Therapeutics Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Stemline Therapeutics Inc Medulloblastoma Drug Product Portfolio Table 123. Stemline Therapeutics Inc Recent Development Table 124. ThromboGenics NV Company Information Table 125. ThromboGenics NV Business Overview Table 126. ThromboGenics NV Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. ThromboGenics NV Medulloblastoma Drug Product Portfolio Table 128. ThromboGenics NV Recent Development Table 129. VBI Vaccines Inc Company Information Table 130. VBI Vaccines Inc Business Overview Table 131. VBI Vaccines Inc Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. VBI Vaccines Inc Medulloblastoma Drug Product Portfolio Table 133. VBI Vaccines Inc Recent Development Table 134. Bristol-Myers Squibb Company Company Information Table 135. Bristol-Myers Squibb Company Business Overview Table 136. Bristol-Myers Squibb Company Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Bristol-Myers Squibb Company Medulloblastoma Drug Product Portfolio Table 138. Bristol-Myers Squibb Company Recent Development Table 139. Bayer AG Company Information Table 140. Bayer AG Business Overview Table 141. Bayer AG Medulloblastoma Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. Bayer AG Medulloblastoma Drug Product Portfolio Table 143. Bayer AG Recent Development Table 144. North America Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 145. North America Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 146. North America Medulloblastoma Drug Sales Market Share by Country (2021-2026) Table 147. North America Medulloblastoma Drug Sales Forecast by Country (2027-2032) & (k units) Table 148. North America Medulloblastoma Drug Sales Market Share Forecast by Country (2027-2032) Table 149. North America Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. North America Medulloblastoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 151. North America Medulloblastoma Drug Market Share by Country (2021-2026) Table 152. North America Medulloblastoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. North America Medulloblastoma Drug Market Share Forecast by Country (2027-2032) Table 154. Europe Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 155. Europe Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 156. Europe Medulloblastoma Drug Sales Market Share by Country (2021-2026) Table 157. Europe Medulloblastoma Drug Sales Forecast by Country (2027-2032) & (k units) Table 158. Europe Medulloblastoma Drug Sales Market Share Forecast by Country (2027-2032) Table 159. Europe Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 160. Europe Medulloblastoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 161. Europe Medulloblastoma Drug Market Share by Country (2021-2026) Table 162. Europe Medulloblastoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 163. Europe Medulloblastoma Drug Market Share Forecast by Country (2027-2032) Table 164. Asia-Pacific Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 165. Asia-Pacific Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 166. Asia-Pacific Medulloblastoma Drug Sales Market Share by Country (2021-2026) Table 167. Asia-Pacific Medulloblastoma Drug Sales Forecast by Country (2027-2032) & (k units) Table 168. Asia-Pacific Medulloblastoma Drug Sales Market Share Forecast by Country (2027-2032) Table 169. Asia-Pacific Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 170. Asia-Pacific Medulloblastoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 171. Asia-Pacific Medulloblastoma Drug Market Share by Country (2021-2026) Table 172. Asia-Pacific Medulloblastoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 173. Asia-Pacific Medulloblastoma Drug Market Share Forecast by Country (2027-2032) Table 174. Latin America Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 175. Latin America Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 176. Latin America Medulloblastoma Drug Sales Market Share by Country (2021-2026) Table 177. Latin America Medulloblastoma Drug Sales Forecast by Country (2027-2032) & (k units) Table 178. Latin America Medulloblastoma Drug Sales Market Share Forecast by Country (2027-2032) Table 179. Latin America Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 180. Latin America Medulloblastoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 181. Latin America Medulloblastoma Drug Market Share by Country (2021-2026) Table 182. Latin America Medulloblastoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 183. Latin America Medulloblastoma Drug Market Share Forecast by Country (2027-2032) Table 184. Middle East and Africa Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 185. Middle East and Africa Medulloblastoma Drug Sales by Country (2021-2026) & (k units) Table 186. Middle East and Africa Medulloblastoma Drug Sales Market Share by Country (2021-2026) Table 187. Middle East and Africa Medulloblastoma Drug Sales Forecast by Country (2027-2032) & (k units) Table 188. Middle East and Africa Medulloblastoma Drug Sales Market Share Forecast by Country (2027-2032) Table 189. Middle East and Africa Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 190. Middle East and Africa Medulloblastoma Drug Market Size by Country (2021-2026) & (US$ Million) Table 191. Middle East and Africa Medulloblastoma Drug Market Share by Country (2021-2026) Table 192. Middle East and Africa Medulloblastoma Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 193. Middle East and Africa Medulloblastoma Drug Market Share Forecast by Country (2027-2032) Table 194. Key Raw Materials Table 195. Raw Materials Key Suppliers Table 196. Medulloblastoma Drug Distributors List Table 197. Medulloblastoma Drug Customers List Table 198. Research Programs/Design for This Report Table 199. Authors List of This Report Table 200. Secondary Sources Table 201. Primary Sources List of Figures Figure 1. Medulloblastoma Drug Image Figure 2. Global Medulloblastoma Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medulloblastoma Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Medulloblastoma Drug Sales (2021-2032) & (k units) Figure 5. Ipilimumab Image Figure 6. Global Ipilimumab Sales YoY Growth (2021-2032) & (k units) Figure 7. Dianhydrogalactitol Image Figure 8. Global Dianhydrogalactitol Sales YoY Growth (2021-2032) & (k units) Figure 9. Indoximod Image Figure 10. Global Indoximod Sales YoY Growth (2021-2032) & (k units) Figure 11. IMP-5471 Image Figure 12. Global IMP-5471 Sales YoY Growth (2021-2032) & (k units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 15. Global Medulloblastoma Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Medulloblastoma Drug Market Share by Type 2025 VS 2032 Figure 17. North America Medulloblastoma Drug Sales Market Share in Volume by Type in 2025 Figure 18. North America Medulloblastoma Drug Sales Market Share in Value by Type in 2025 Figure 19. Europe Medulloblastoma Drug Sales Market Share in Volume by Type in 2025 Figure 20. Europe Medulloblastoma Drug Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Medulloblastoma Drug Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Medulloblastoma Drug Sales Market Share in Value by Type in 2025 Figure 23. Latin America Medulloblastoma Drug Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Medulloblastoma Drug Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Medulloblastoma Drug Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Medulloblastoma Drug Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Medulloblastoma Drug Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 35. Global Medulloblastoma Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Medulloblastoma Drug Market Share by Application 2025 VS 2032 Figure 37. North America Medulloblastoma Drug Sales Market Share in Volume by Application in 2025 Figure 38. North America Medulloblastoma Drug Sales Market Share in Value by Application in 2025 Figure 39. Europe Medulloblastoma Drug Sales Market Share in Volume by Application in 2025 Figure 40. Europe Medulloblastoma Drug Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Medulloblastoma Drug Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Medulloblastoma Drug Sales Market Share in Value by Application in 2025 Figure 43. Latin America Medulloblastoma Drug Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Medulloblastoma Drug Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Medulloblastoma Drug Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Medulloblastoma Drug Sales Market Share in Value by Application in 2025 Figure 47. North America Medulloblastoma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. North America Medulloblastoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Medulloblastoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Medulloblastoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Medulloblastoma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Europe Medulloblastoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Medulloblastoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Medulloblastoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Medulloblastoma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Asia-Pacific Medulloblastoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Medulloblastoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Medulloblastoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Medulloblastoma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Latin America Medulloblastoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Medulloblastoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Medulloblastoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Medulloblastoma Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 64. Middle East and Africa Medulloblastoma Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Medulloblastoma Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Medulloblastoma Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Medulloblastoma Drug Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Medulloblastoma Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Ipilimumab
  • Dianhydrogalactitol
  • Indoximod
  • IMP-5471
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • DelMar Pharmaceuticals Inc
  • Ignyta Inc
  • IMPACT Therapeutics Inc
  • Lipocure Ltd
  • MacroGenics Inc
  • NewLink Genetics Corp
  • Novogen Ltd
  • Ono Pharmaceutical Co Ltd
  • Progenics Pharmaceuticals Inc
  • Stemline Therapeutics Inc
  • ThromboGenics NV
  • VBI Vaccines Inc
  • Bristol-Myers Squibb Company
  • Bayer AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Medulloblastoma Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Medulloblastoma Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Medulloblastoma Drug Market by Type
  6. 1.3.1 Ipilimumab
  7. 1.3.2 Dianhydrogalactitol
  8. 1.3.3 Indoximod
  9. 1.3.4 IMP-5471
  10. 1.3.5 Others
  11. 1.4 Global Medulloblastoma Drug Market Size by Type
  12. 1.4.1 Global Medulloblastoma Drug Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Medulloblastoma Drug Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Medulloblastoma Drug Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Medulloblastoma Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Medulloblastoma Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Medulloblastoma Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Medulloblastoma Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Medulloblastoma Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Medulloblastoma Drug Industry Trends
  2. 2.2 Medulloblastoma Drug Industry Drivers
  3. 2.3 Medulloblastoma Drug Industry Opportunities and Challenges
  4. 2.4 Medulloblastoma Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Medulloblastoma Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Medulloblastoma Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Medulloblastoma Drug Price (2021-2026)
  4. 3.4 Global Medulloblastoma Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Medulloblastoma Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Medulloblastoma Drug Company, Product Type & Application
  7. 3.7 Global Medulloblastoma Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Medulloblastoma Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Medulloblastoma Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Medulloblastoma Drug Tier 1, Tier 2, and Tier 3
4 Medulloblastoma Drug Regional Status and Outlook
  1. 4.1 Global Medulloblastoma Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Medulloblastoma Drug Historic Market Size by Region
  3. 4.2.1 Global Medulloblastoma Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Medulloblastoma Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Medulloblastoma Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Medulloblastoma Drug Forecasted Market Size by Region
  7. 4.3.1 Global Medulloblastoma Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Medulloblastoma Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Medulloblastoma Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Medulloblastoma Drug by Application
  1. 5.1 Medulloblastoma Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Medulloblastoma Drug Market Size by Application
  6. 5.2.1 Global Medulloblastoma Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Medulloblastoma Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Medulloblastoma Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Medulloblastoma Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Medulloblastoma Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Medulloblastoma Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Medulloblastoma Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Medulloblastoma Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 DelMar Pharmaceuticals Inc
  2. 6.1.1 DelMar Pharmaceuticals Inc Company Information
  3. 6.1.2 DelMar Pharmaceuticals Inc Business Overview
  4. 6.1.3 DelMar Pharmaceuticals Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 DelMar Pharmaceuticals Inc Medulloblastoma Drug Product Portfolio
  6. 6.1.5 DelMar Pharmaceuticals Inc Recent Developments
  7. 6.2 Ignyta Inc
  8. 6.2.1 Ignyta Inc Company Information
  9. 6.2.2 Ignyta Inc Business Overview
  10. 6.2.3 Ignyta Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Ignyta Inc Medulloblastoma Drug Product Portfolio
  12. 6.2.5 Ignyta Inc Recent Developments
  13. 6.3 IMPACT Therapeutics Inc
  14. 6.3.1 IMPACT Therapeutics Inc Company Information
  15. 6.3.2 IMPACT Therapeutics Inc Business Overview
  16. 6.3.3 IMPACT Therapeutics Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 IMPACT Therapeutics Inc Medulloblastoma Drug Product Portfolio
  18. 6.3.5 IMPACT Therapeutics Inc Recent Developments
  19. 6.4 Lipocure Ltd
  20. 6.4.1 Lipocure Ltd Company Information
  21. 6.4.2 Lipocure Ltd Business Overview
  22. 6.4.3 Lipocure Ltd Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Lipocure Ltd Medulloblastoma Drug Product Portfolio
  24. 6.4.5 Lipocure Ltd Recent Developments
  25. 6.5 MacroGenics Inc
  26. 6.5.1 MacroGenics Inc Company Information
  27. 6.5.2 MacroGenics Inc Business Overview
  28. 6.5.3 MacroGenics Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 MacroGenics Inc Medulloblastoma Drug Product Portfolio
  30. 6.5.5 MacroGenics Inc Recent Developments
  31. 6.6 NewLink Genetics Corp
  32. 6.6.1 NewLink Genetics Corp Company Information
  33. 6.6.2 NewLink Genetics Corp Business Overview
  34. 6.6.3 NewLink Genetics Corp Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 NewLink Genetics Corp Medulloblastoma Drug Product Portfolio
  36. 6.6.5 NewLink Genetics Corp Recent Developments
  37. 6.7 Novogen Ltd
  38. 6.7.1 Novogen Ltd Company Information
  39. 6.7.2 Novogen Ltd Business Overview
  40. 6.7.3 Novogen Ltd Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Novogen Ltd Medulloblastoma Drug Product Portfolio
  42. 6.7.5 Novogen Ltd Recent Developments
  43. 6.8 Ono Pharmaceutical Co Ltd
  44. 6.8.1 Ono Pharmaceutical Co Ltd Company Information
  45. 6.8.2 Ono Pharmaceutical Co Ltd Business Overview
  46. 6.8.3 Ono Pharmaceutical Co Ltd Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Ono Pharmaceutical Co Ltd Medulloblastoma Drug Product Portfolio
  48. 6.8.5 Ono Pharmaceutical Co Ltd Recent Developments
  49. 6.9 Progenics Pharmaceuticals Inc
  50. 6.9.1 Progenics Pharmaceuticals Inc Company Information
  51. 6.9.2 Progenics Pharmaceuticals Inc Business Overview
  52. 6.9.3 Progenics Pharmaceuticals Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Progenics Pharmaceuticals Inc Medulloblastoma Drug Product Portfolio
  54. 6.9.5 Progenics Pharmaceuticals Inc Recent Developments
  55. 6.10 Stemline Therapeutics Inc
  56. 6.10.1 Stemline Therapeutics Inc Company Information
  57. 6.10.2 Stemline Therapeutics Inc Business Overview
  58. 6.10.3 Stemline Therapeutics Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Stemline Therapeutics Inc Medulloblastoma Drug Product Portfolio
  60. 6.10.5 Stemline Therapeutics Inc Recent Developments
  61. 6.11 ThromboGenics NV
  62. 6.11.1 ThromboGenics NV Company Information
  63. 6.11.2 ThromboGenics NV Business Overview
  64. 6.11.3 ThromboGenics NV Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 ThromboGenics NV Medulloblastoma Drug Product Portfolio
  66. 6.11.5 ThromboGenics NV Recent Developments
  67. 6.12 VBI Vaccines Inc
  68. 6.12.1 VBI Vaccines Inc Company Information
  69. 6.12.2 VBI Vaccines Inc Business Overview
  70. 6.12.3 VBI Vaccines Inc Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 VBI Vaccines Inc Medulloblastoma Drug Product Portfolio
  72. 6.12.5 VBI Vaccines Inc Recent Developments
  73. 6.13 Bristol-Myers Squibb Company
  74. 6.13.1 Bristol-Myers Squibb Company Company Information
  75. 6.13.2 Bristol-Myers Squibb Company Business Overview
  76. 6.13.3 Bristol-Myers Squibb Company Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Bristol-Myers Squibb Company Medulloblastoma Drug Product Portfolio
  78. 6.13.5 Bristol-Myers Squibb Company Recent Developments
  79. 6.14 Bayer AG
  80. 6.14.1 Bayer AG Company Information
  81. 6.14.2 Bayer AG Business Overview
  82. 6.14.3 Bayer AG Medulloblastoma Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Bayer AG Medulloblastoma Drug Product Portfolio
  84. 6.14.5 Bayer AG Recent Developments
7 North America by Country
  1. 7.1 North America Medulloblastoma Drug Sales by Country
  2. 7.1.1 North America Medulloblastoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Medulloblastoma Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Medulloblastoma Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Medulloblastoma Drug Market Size by Country
  6. 7.2.1 North America Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Medulloblastoma Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Medulloblastoma Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Medulloblastoma Drug Sales by Country
  2. 8.1.1 Europe Medulloblastoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Medulloblastoma Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Medulloblastoma Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Medulloblastoma Drug Market Size by Country
  6. 8.2.1 Europe Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Medulloblastoma Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Medulloblastoma Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Medulloblastoma Drug Sales by Country
  2. 9.1.1 Asia-Pacific Medulloblastoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Medulloblastoma Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Medulloblastoma Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Medulloblastoma Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Medulloblastoma Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Medulloblastoma Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Medulloblastoma Drug Sales by Country
  2. 10.1.1 South America Medulloblastoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Medulloblastoma Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Medulloblastoma Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Medulloblastoma Drug Market Size by Country
  6. 10.2.1 South America Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Medulloblastoma Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Medulloblastoma Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Medulloblastoma Drug Sales by Country
  2. 11.1.1 Middle East and Africa Medulloblastoma Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Medulloblastoma Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Medulloblastoma Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Medulloblastoma Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Medulloblastoma Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Medulloblastoma Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Medulloblastoma Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Medulloblastoma Drug Value Chain Analysis
  2. 12.1.1 Medulloblastoma Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Medulloblastoma Drug Production Mode & Process
  7. 12.2 Medulloblastoma Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Medulloblastoma Drug Distributors
  10. 12.2.3 Medulloblastoma Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst